NRX-101: First Antidepressant to Lower Suicidality in Bipolar Depression

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality.

Related Keywords

United States ,Florida ,Miami Beach ,Massachusetts ,New York ,American ,Andrew Nierenberg ,Jonathan Javitt ,Drug Administration ,American Psychiatric Association ,Dauten Family Center ,Nrx Pharmaceuticals Nasdaq ,Psychiatry At Harvard Medical School ,American Society Of Clinical Psychopharmacology ,Nrx Pharmaceuticals ,Massachusetts General Hospital ,American Society ,Clinical Psychopharmacology ,Chief Scientist ,Bipolar Treatment Innovation ,Harvard Medical School ,Columbia Suicide Severity Rating Scale ,Effect Size ,Barnes Akathisia Rating ,Psychiatric Association ,Presents Landmark Trial ,Clinical Psychopharmacology Annual Meeting ,First Oral Antidepressant Demonstrated ,Reduce Suicidality ,Therapy Designation ,First Oral Drug Targeting Suicidal Bipolar ,Pivotal Studies ,